[go: up one dir, main page]

MX2020008103A - Metodos y composiciones para polarizacion de macrofagos. - Google Patents

Metodos y composiciones para polarizacion de macrofagos.

Info

Publication number
MX2020008103A
MX2020008103A MX2020008103A MX2020008103A MX2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A MX 2020008103 A MX2020008103 A MX 2020008103A
Authority
MX
Mexico
Prior art keywords
compositions
methods
macrophage polarization
polarization
macrophage
Prior art date
Application number
MX2020008103A
Other languages
English (en)
Inventor
Sriram Sathyanarayanan
Douglas E Williams
Dalia Burzyn
Adam Thomas Boutin
Sushrut Kamerkar
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2020008103A publication Critical patent/MX2020008103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen composiciones y métodos que comprenden vesículas extracelulares que comprenden ácido nucleico que se dirige a genes, lo que conduce a la polarización de macrófagos de macrófagos asociados a tumores. En ciertas modalidades, en la presente se describen métodos y composiciones para aumentar la polarización de macrófagos para el tratamiento del cáncer.
MX2020008103A 2018-02-12 2019-02-12 Metodos y composiciones para polarizacion de macrofagos. MX2020008103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629563P 2018-02-12 2018-02-12
PCT/US2019/017731 WO2019157535A1 (en) 2018-02-12 2019-02-12 Methods and compositions for macrophage polarization

Publications (1)

Publication Number Publication Date
MX2020008103A true MX2020008103A (es) 2020-09-25

Family

ID=65729420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008103A MX2020008103A (es) 2018-02-12 2019-02-12 Metodos y composiciones para polarizacion de macrofagos.

Country Status (17)

Country Link
US (2) US11512315B2 (es)
EP (1) EP3752615A1 (es)
JP (2) JP2021512608A (es)
KR (1) KR20200120624A (es)
CN (2) CN119614501A (es)
AU (1) AU2019218991A1 (es)
BR (1) BR112020016228A2 (es)
CA (1) CA3088009A1 (es)
CL (1) CL2020002053A1 (es)
CO (1) CO2020009694A2 (es)
EA (1) EA202091486A1 (es)
IL (1) IL276409A (es)
MX (1) MX2020008103A (es)
PH (1) PH12020551195A1 (es)
SG (1) SG11202006021SA (es)
TW (1) TW202003846A (es)
WO (1) WO2019157535A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119614501A (zh) 2018-02-12 2025-03-14 隆萨销售股份公司 用于巨噬细胞极化的方法和组合物
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease
WO2020106772A1 (en) * 2018-11-19 2020-05-28 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
AU2020327360A1 (en) * 2019-08-14 2022-02-17 Lonza Sales Ag Extracellular vesicle linked to molecules and uses thereof
CA3147366A1 (en) * 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
US20230018254A1 (en) * 2019-08-14 2023-01-19 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
CN114729356A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
BR112022002690A2 (pt) * 2019-08-14 2022-08-23 Codiak Biosciences Inc Construtos de vesícula-aso extracelular tendo como alvo cebp/beta
US20240099973A1 (en) * 2019-09-25 2024-03-28 Lonza Sales Ag Extracellular vesicle compositions
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
US20230190815A1 (en) 2020-05-11 2023-06-22 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles
WO2021237100A1 (en) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111748523B (zh) * 2020-07-17 2022-11-22 南通大学 一种免疫调节小胞外囊泡的制备方法及其用途
WO2022076596A1 (en) * 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN113262305B (zh) * 2021-05-27 2022-03-25 浙江大学 Coro1a基因作为靶点在制备抗肿瘤药物中的应用
CN117897386A (zh) 2021-07-02 2024-04-16 斯帕克生物制药有限公司 苯并吡喃衍生物及其用途
CN113521252B (zh) * 2021-07-29 2022-12-20 南开大学 Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法
WO2023069628A2 (en) * 2021-10-21 2023-04-27 Nanothera Biosciences, Inc. Compositions and methods for silencing kras
CN114058621B (zh) * 2021-12-03 2023-06-16 温州医科大学 一种lncRNA基因修饰细胞分泌的外泌体及应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114561347A (zh) * 2022-02-25 2022-05-31 和携科技有限公司 一种脂肪间充质干细胞的培养基和培养方法
CN115137708B (zh) * 2022-06-24 2023-05-16 重庆医科大学 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用
EP4554984A1 (en) * 2022-07-13 2025-05-21 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
WO2024044788A2 (en) * 2022-08-26 2024-02-29 Georgia State University Research Foundation, Inc. Treating chronic inflammation and cancer by macrophage polarization
CN115814108B (zh) * 2022-12-27 2025-04-25 华中科技大学 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法
CN116370647B (zh) * 2023-04-11 2025-07-11 吉林大学 一种用于胰腺癌免疫治疗的工程化外泌体及制备方法
CN119215144A (zh) * 2023-09-08 2024-12-31 首都医科大学附属北京朝阳医院 Lrg1在制备促进巨噬细胞向m1型分化的药物中的应用和巨噬细胞激活剂
KR102635831B1 (ko) * 2023-11-01 2024-02-13 강원대학교 산학협력단 Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6860201A (en) * 2000-06-19 2002-01-02 Halliburton Energy Serv Inc Apparatus and methods for applying time lapse vsp to monitor a reservoir
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
CN103555722B (zh) * 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
EP3057662A4 (en) * 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
AU2015335029B2 (en) * 2014-10-24 2021-09-23 Astrazeneca Ab Combination
CA2988585A1 (en) * 2015-06-10 2016-12-15 Raghu Kalluri Use of exosomes for the treatment of disease
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
WO2017053722A1 (en) 2015-09-24 2017-03-30 Ionis Pharmaceuticals, Inc. Modulators of kras expression
KR20180122433A (ko) 2016-03-15 2018-11-12 코디악 바이오사이언시즈, 인크. 치료용 막 소포
WO2018039119A1 (en) 2016-08-22 2018-03-01 Codiak Biosciences, Inc. Methods of suppressing delivery of exosomes to liver and spleen
IL272786B2 (en) 2017-08-25 2025-03-01 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
CN119614501A (zh) 2018-02-12 2025-03-14 隆萨销售股份公司 用于巨噬细胞极化的方法和组合物
AU2020327360A1 (en) * 2019-08-14 2022-02-17 Lonza Sales Ag Extracellular vesicle linked to molecules and uses thereof
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
US20250163150A1 (en) * 2022-03-04 2025-05-22 I-Mab Biopharma Us Limited Combination therapies comprising a kras inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
CA3088009A1 (en) 2019-08-15
TW202003846A (zh) 2020-01-16
CL2020002053A1 (es) 2020-12-18
CO2020009694A2 (es) 2020-10-30
PH12020551195A1 (en) 2021-08-16
CN111918967B (zh) 2024-11-19
JP2024166292A (ja) 2024-11-28
US20200407725A1 (en) 2020-12-31
AU2019218991A1 (en) 2020-07-09
IL276409A (en) 2020-09-30
CN119614501A (zh) 2025-03-14
BR112020016228A2 (pt) 2020-12-08
KR20200120624A (ko) 2020-10-21
US20230365971A1 (en) 2023-11-16
JP2021512608A (ja) 2021-05-20
EA202091486A1 (ru) 2021-02-08
CN111918967A (zh) 2020-11-10
EP3752615A1 (en) 2020-12-23
WO2019157535A1 (en) 2019-08-15
SG11202006021SA (en) 2020-08-28
US11512315B2 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
MX2020008103A (es) Metodos y composiciones para polarizacion de macrofagos.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
PE20210633A1 (es) CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESION DE PNPLA3 Y METODOS DE USO DE LOS MISMOS
UY36075A (es) Derivados de tubulisina
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
UY35385A (es) ?métodos y composiciones para el control de malezas?.
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
MX387916B (es) Constructo de expresión para la producción transitoria de una proteína terapéutica casp9 en una célula objetivo senescente humana.
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
DOP2016000072A (es) Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.